ACR vs ONL

ACR exhibits weak financial health with a Piotroski F-Score of just 2/9, signaling significant operational and balance sheet concerns. Despite strong recent earnings growth and profitability margins, the company's high leverage (Debt/Equity of 2.84) and extremely low valuation multiples like Price/Book of 0.32 suggest deep underlying risks. The absence of an Altman Z-Score due to insufficient data further clouds solvency assessment, while technical indicators and insider sentiment are neutral-to-bearish. Although the stock appears undervalued relative to the Graham Number ($35.84) and analyst target ($24.50), erratic earnings surprises and lack of dividend support undermine confidence in sustained recovery.

The company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a disastrous profit margin of -102.56%. While the stock trades at a deep discount to book value (P/B 0.26), this is likely a value trap given the -36.60% YoY revenue decline and consistent negative earnings. Recent short-term price momentum is disconnected from the underlying fundamental decay and long-term 5-year decline of 80.1%. The lack of an Altman Z-Score prevents a definitive bankruptcy trigger, but the deterministic health metrics are critically low.